Researcher believes that nanobody helps in the treatment against COVID-19.
Researchers at the Karolinska Institute in Sweden have identified a nanobody small neutralizing antibody that has the potential to prevent SARS-COV-2 from entering human cells.
Researchers believe that this nano has the potential to develop as an antiviral treatment against COVID-19. The results are published in the journal Nature Communications.
“We hope that our findings can contribute to the modification of the COVID-19 epidemic by encouraging further examination of this nano as a therapeutic candidate against this viral infection,” corresponding author and associate professor of virology at the Department of Microbiology Gerald McInnern said. Tumors, and Cell Biology at Karolinska Institute.
The discovery of effective nanobodies that are fragments of antibodies that occur naturally in camels and may have been adapted for humans when an alpaca was injected with the new coronovirus spike protein in February was used to enter our cells Is done for After 60 days, blood samples from the alpaca showed a strong immune response against the spike protein.
Subsequently, the researchers cloned, enriched and analyzed from alpaca’s B cells, a type of white blood cell, to determine which nanobodies were best suited for further evaluation. They identified one, Ty1 (named after Alpaca Tyson), which efficiently neutralizes the virus by attaching itself to the portion of the spike protein that binds the receptor ACE2, using SARS-CoV-2. Is used to infect cells. This prevents the virus from slipping into the cells and thus prevents infection.
“Using cryo-electron microscopy, we were able to see how any one binds a viral spike on the epitope, which overlaps with the cellular receptor ACE2-binding site, providing a structural understanding for PotO neutralization activity Is, ”said Leo Hanke. Post doctor and the first author of the study in the McInerney group.
Nano antibodies as candidates for specific therapies offer several advantages over traditional antibodies. They are less than one-tenth the size of conventional antibodies and are generally easy to produce cost-effectively. Critically, they can be adapted to humans with current protocols and have a proven record of preventing viral respiratory infections.
“Our results suggest that Ty1 can potently bind the SARS-CoV-2 spike protein and neutralize viruses that have no detectable targeting activity. We now have the neutralizing activity and therapeutic potential of Ty1 Are considering preclinical animal studies to investigate. Vivo, “said Ben Murrell, Department of Microbiology, Assistant Professor of Tumor and Cell Biology and co-senior author of the publication.
The project is the first project to originate from the Coroenb consortium, coordinated by the Karolinska Institute, and funded by the European Union’s Horizon 2020 research and innovation program. Additional funding for this project was obtained from the Swedish Research Council and the KI Development Office.